Connection

Francis Spinale to Ventricular Remodeling

This is a "connection" page, showing publications Francis Spinale has written about Ventricular Remodeling.
Connection Strength

17.219
  1. Ubiquitin ligase Wwp1 gene deletion attenuates diastolic dysfunction in pressure-overload hypertrophy. Am J Physiol Heart Circ Physiol. 2021 11 01; 321(5):H976-H984.
    View in: PubMed
    Score: 0.616
  2. Targeted Injection of a Truncated Form of Tissue Inhibitor of Metalloproteinase 3 Alters Post-Myocardial Infarction Remodeling. J Pharmacol Exp Ther. 2020 11; 375(2):296-307.
    View in: PubMed
    Score: 0.575
  3. The ubiquitin ligase WWP1 contributes to shifts in matrix proteolytic profiles and a myocardial aging phenotype with diastolic heart. Am J Physiol Heart Circ Physiol. 2020 10 01; 319(4):H765-H774.
    View in: PubMed
    Score: 0.571
  4. Regional and temporal changes in left ventricular strain and stiffness in a porcine model of myocardial infarction. Am J Physiol Heart Circ Physiol. 2018 10 01; 315(4):H958-H967.
    View in: PubMed
    Score: 0.494
  5. Delivery of a matrix metalloproteinase-responsive hydrogel releasing TIMP-3 after myocardial infarction: effects on left ventricular remodeling. Am J Physiol Heart Circ Physiol. 2018 10 01; 315(4):H814-H825.
    View in: PubMed
    Score: 0.493
  6. Intracoronary delivery of recombinant TIMP-3 after myocardial infarction: effects on myocardial remodeling and function. Am J Physiol Heart Circ Physiol. 2017 Oct 01; 313(4):H690-H699.
    View in: PubMed
    Score: 0.462
  7. In vivo assessment of regional mechanics post-myocardial infarction: A focus on the road ahead. J Appl Physiol (1985). 2017 Oct 01; 123(4):728-745.
    View in: PubMed
    Score: 0.448
  8. Crossing Into the Next Frontier of Cardiac Extracellular Matrix Research. Circ Res. 2016 10 28; 119(10):1040-1045.
    View in: PubMed
    Score: 0.439
  9. Sonomicrometry-Based Analysis of Post-Myocardial Infarction Regional Mechanics. Ann Biomed Eng. 2016 12; 44(12):3539-3552.
    View in: PubMed
    Score: 0.430
  10. Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophy. Am J Physiol Heart Circ Physiol. 2014 Sep 01; 307(5):H752-61.
    View in: PubMed
    Score: 0.373
  11. Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice. Circ Res. 2014 Apr 25; 114(9):1435-45.
    View in: PubMed
    Score: 0.366
  12. Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction. Sci Transl Med. 2014 Feb 12; 6(223):223ra21.
    View in: PubMed
    Score: 0.364
  13. Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload. Circ Heart Fail. 2014 Mar 01; 7(2):340-50.
    View in: PubMed
    Score: 0.361
  14. Localized targeting of biomaterials following myocardial infarction: a foundation to build on. Trends Cardiovasc Med. 2013 Nov; 23(8):301-11.
    View in: PubMed
    Score: 0.347
  15. Membrane-associated matrix proteolysis and heart failure. Circ Res. 2013 Jan 04; 112(1):195-208.
    View in: PubMed
    Score: 0.337
  16. Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol. 2012 Apr 01; 302(7):H1429-37.
    View in: PubMed
    Score: 0.315
  17. Changes in the myocardial interstitium and contribution to the progression of heart failure. Heart Fail Clin. 2012 Jan; 8(1):7-20.
    View in: PubMed
    Score: 0.314
  18. Diversity of myocardial interstitial proteolytic pathways: gene deletion reveals unexpected consequences. Circulation. 2011 Nov 08; 124(19):2052-5.
    View in: PubMed
    Score: 0.311
  19. Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature. J Thorac Cardiovasc Surg. 2012 Jan; 143(1):215-23.
    View in: PubMed
    Score: 0.310
  20. Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. Circ Cardiovasc Genet. 2011 Dec; 4(6):614-9.
    View in: PubMed
    Score: 0.308
  21. Targeted regional injection of biocomposite microspheres alters post-myocardial infarction remodeling and matrix proteolytic pathways. Circulation. 2011 Sep 13; 124(11 Suppl):S35-45.
    View in: PubMed
    Score: 0.307
  22. Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. J Thorac Cardiovasc Surg. 2012 Mar; 143(3):656-64.
    View in: PubMed
    Score: 0.304
  23. Direct regulation of membrane type 1 matrix metalloproteinase following myocardial infarction causes changes in survival, cardiac function, and remodeling. Am J Physiol Heart Circ Physiol. 2011 Oct; 301(4):H1656-66.
    View in: PubMed
    Score: 0.302
  24. Myocardial remodeling: cellular and extracellular events and targets. Annu Rev Physiol. 2011; 73:47-68.
    View in: PubMed
    Score: 0.293
  25. Heterogeneity in MT1-MMP activity with ischemia-reperfusion and previous myocardial infarction: relation to regional myocardial function. Am J Physiol Heart Circ Physiol. 2010 Dec; 299(6):H1947-58.
    View in: PubMed
    Score: 0.288
  26. Cardiac restricted overexpression of membrane type-1 matrix metalloproteinase causes adverse myocardial remodeling following myocardial infarction. J Biol Chem. 2010 Sep 24; 285(39):30316-27.
    View in: PubMed
    Score: 0.284
  27. Amplified bioactive signaling and proteolytic enzymes following ischemia reperfusion and aging: remodeling pathways that are not like a fine wine. Circulation. 2010 Jul 27; 122(4):322-4.
    View in: PubMed
    Score: 0.283
  28. Long-term localized high-frequency electric stimulation within the myocardial infarct: effects on matrix metalloproteinases and regional remodeling. Circulation. 2010 Jul 06; 122(1):20-32.
    View in: PubMed
    Score: 0.282
  29. Short-term disruption in regional left ventricular electrical conduction patterns increases interstitial matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol. 2010 Jul; 299(1):H217-24.
    View in: PubMed
    Score: 0.280
  30. Pathophysiology of myocardial injury and remodeling: implications for molecular imaging. J Nucl Med. 2010 May 01; 51 Suppl 1:102S-106S.
    View in: PubMed
    Score: 0.279
  31. Caspase inhibition modulates left ventricular remodeling following myocardial infarction through cellular and extracellular mechanisms. J Cardiovasc Pharmacol. 2010 Apr; 55(4):408-16.
    View in: PubMed
    Score: 0.278
  32. Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. Circulation. 2009 Sep 15; 120(11 Suppl):S220-9.
    View in: PubMed
    Score: 0.268
  33. Cardiac-restricted overexpression of membrane type-1 matrix metalloproteinase in mice: effects on myocardial remodeling with aging. Circ Heart Fail. 2009 Jul; 2(4):351-60.
    View in: PubMed
    Score: 0.261
  34. Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in pigs. Ann Thorac Surg. 2008 Oct; 86(4):1268-76.
    View in: PubMed
    Score: 0.251
  35. Cardiac-restricted overexpression of extracellular matrix metalloproteinase inducer causes myocardial remodeling and dysfunction in aging mice. Am J Physiol Heart Circ Physiol. 2008 Oct; 295(4):H1394-402.
    View in: PubMed
    Score: 0.248
  36. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007 Oct; 87(4):1285-342.
    View in: PubMed
    Score: 0.234
  37. Alterations in cultured myocardial fibroblast function following the development of left ventricular failure. J Mol Cell Cardiol. 2006 Apr; 40(4):474-83.
    View in: PubMed
    Score: 0.210
  38. Selective targeting of matrix metalloproteinase inhibition in post-infarction myocardial remodeling. J Cardiovasc Pharmacol. 2006 Feb; 47(2):228-35.
    View in: PubMed
    Score: 0.208
  39. Cardiac support device modifies left ventricular geometry and myocardial structure after myocardial infarction. Circulation. 2005 Aug 30; 112(9):1274-83.
    View in: PubMed
    Score: 0.202
  40. Matrix modulation and heart failure: new concepts question old beliefs. Curr Opin Cardiol. 2005 May; 20(3):211-6.
    View in: PubMed
    Score: 0.198
  41. Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol. 2005 Jan; 288(1):H149-58.
    View in: PubMed
    Score: 0.193
  42. Pharmacologic inhibition of intracellular caspases after myocardial infarction attenuates left ventricular remodeling: a potentially novel pathway. J Thorac Cardiovasc Surg. 2003 Dec; 126(6):1892-9.
    View in: PubMed
    Score: 0.179
  43. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation. 2003 Jun 10; 107(22):2857-63.
    View in: PubMed
    Score: 0.173
  44. Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs. J Thorac Cardiovasc Surg. 2003 Mar; 125(3):602-10.
    View in: PubMed
    Score: 0.170
  45. Extracellular matrix remodeling following myocardial injury. Ann Med. 2003; 35(5):316-26.
    View in: PubMed
    Score: 0.168
  46. Tissue inhibitor of metalloproteinase-4 deletion in mice impacts maternal cardiac function during pregnancy and postpartum. Am J Physiol Heart Circ Physiol. 2023 01 01; 324(1):H85-H99.
    View in: PubMed
    Score: 0.167
  47. Extracellular degradative pathways in myocardial remodeling and progression to heart failure. J Card Fail. 2002 Dec; 8(6 Suppl):S332-8.
    View in: PubMed
    Score: 0.167
  48. The extracellular matrix: summation. J Card Fail. 2002 Dec; 8(6 Suppl):S349-50.
    View in: PubMed
    Score: 0.167
  49. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res. 2002 Mar; 53(4):822-30.
    View in: PubMed
    Score: 0.159
  50. Regional heterogeneity in determinants of atrial matrix remodeling and association with atrial fibrillation vulnerability postmyocardial infarction. Heart Rhythm. 2022 05; 19(5):847-855.
    View in: PubMed
    Score: 0.158
  51. Speckle-Tracking Echocardiography Enables Model-Based Identification of Regional Stiffness Indices in the Left Ventricular Myocardium. Cardiovasc Eng Technol. 2020 04; 11(2):176-187.
    View in: PubMed
    Score: 0.137
  52. Application of Hybrid Matrix Metalloproteinase-Targeted and Dynamic 201Tl Single-Photon Emission Computed Tomography/Computed Tomography Imaging for Evaluation of Early Post-Myocardial Infarction Remodeling. Circ Cardiovasc Imaging. 2019 11; 12(11):e009055.
    View in: PubMed
    Score: 0.135
  53. Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors. Biochem Pharmacol. 2014 Jul 01; 90(1):7-15.
    View in: PubMed
    Score: 0.092
  54. Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition. Nat Mater. 2014 Jun; 13(6):653-61.
    View in: PubMed
    Score: 0.092
  55. Reply to "letter to the editor: 'cyclosporin A in left ventricular remodeling after myocardial infarction'". Am J Physiol Heart Circ Physiol. 2014 Mar 01; 306(5):H778-9.
    View in: PubMed
    Score: 0.091
  56. Cyclosporin A in left ventricular remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol. 2014 Jan 01; 306(1):H53-9.
    View in: PubMed
    Score: 0.089
  57. Gender differences in non-ischemic myocardial remodeling: are they due to estrogen modulation of cardiac mast cells and/or membrane type 1 matrix metalloproteinase. Pflugers Arch. 2013 May; 465(5):687-97.
    View in: PubMed
    Score: 0.085
  58. Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am J Physiol Cell Physiol. 2013 Mar 01; 304(5):C393-402.
    View in: PubMed
    Score: 0.083
  59. Gene targeting in ischemic heart disease and failure: translational and clinical studies. Biochem Pharmacol. 2013 Jan 01; 85(1):1-11.
    View in: PubMed
    Score: 0.082
  60. Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ Cardiovasc Imaging. 2011 Jul; 4(4):381-91.
    View in: PubMed
    Score: 0.075
  61. Discordant activation of gene promoters for matrix metalloproteinases and tissue inhibitors of the metalloproteinases following myocardial infarction. J Surg Res. 2012 Jan; 172(1):59-67.
    View in: PubMed
    Score: 0.071
  62. Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J Am Coll Cardiol. 2008 Jan 29; 51(4):476-86.
    View in: PubMed
    Score: 0.060
  63. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation. 2006 Sep 05; 114(10):1020-7.
    View in: PubMed
    Score: 0.054
  64. Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation. 2006 Jun 27; 113(25):2919-28.
    View in: PubMed
    Score: 0.053
  65. Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006 Nov; 291(5):H2216-28.
    View in: PubMed
    Score: 0.053
  66. From tadpole tails to transgenic mice: metalloproteinases have brought about a metamorphosis in our understanding of cardiovascular disease. Cardiovasc Res. 2006 Feb 15; 69(3):559-61.
    View in: PubMed
    Score: 0.052
  67. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation. 2005 Nov 15; 112(20):3157-67.
    View in: PubMed
    Score: 0.051
  68. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006 Jan; 290(1):H232-9.
    View in: PubMed
    Score: 0.051
  69. Infarct size reduction and attenuation of global left ventricular remodeling with the CorCap cardiac support device following acute myocardial infarction in sheep. Heart Fail Rev. 2005 Jun; 10(2):125-39.
    View in: PubMed
    Score: 0.050
  70. Myocardial interstitial matrix metalloproteinase activity is altered by mechanical changes in LV load: interaction with the angiotensin type 1 receptor. Circ Res. 2005 May 27; 96(10):1110-8.
    View in: PubMed
    Score: 0.049
  71. Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Card Fail. 2005 Mar; 11(2):124-30.
    View in: PubMed
    Score: 0.049
  72. Disruptions and detours in the myocardial matrix highway and heart failure. Curr Heart Fail Rep. 2005 Mar; 2(1):10-7.
    View in: PubMed
    Score: 0.049
  73. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation. 2004 Jan 20; 109(2):262-8.
    View in: PubMed
    Score: 0.045
  74. Myocardial remodeling after discrete radiofrequency injury: effects of tissue inhibitor of matrix metalloproteinase-1 gene deletion. Am J Physiol Heart Circ Physiol. 2004 Apr; 286(4):H1242-7.
    View in: PubMed
    Score: 0.045
  75. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation. 2003 Oct 07; 108(14):1753-9.
    View in: PubMed
    Score: 0.044
  76. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003 Feb 04; 107(4):618-25.
    View in: PubMed
    Score: 0.042
  77. Bioactive peptide signaling within the myocardial interstitium and the matrix metalloproteinases. Circ Res. 2002 Dec 13; 91(12):1082-4.
    View in: PubMed
    Score: 0.042
  78. Matrix Metalloproteinase-Targeted SPECT/CT Imaging for Evaluation of Therapeutic Hydrogels for the Early Modulation of Post-Infarct Myocardial Remodeling. J Cardiovasc Transl Res. 2023 Feb; 16(1):155-165.
    View in: PubMed
    Score: 0.040
  79. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002 Mar 22; 90(5):520-30.
    View in: PubMed
    Score: 0.040
  80. Inhibition of class I histone deacetylase activity represses matrix metalloproteinase-2 and -9 expression and preserves LV function postmyocardial infarction. Am J Physiol Heart Circ Physiol. 2015 Jun 01; 308(11):H1391-401.
    View in: PubMed
    Score: 0.025
  81. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation. 2010 May 04; 121(17):1912-25.
    View in: PubMed
    Score: 0.017
  82. Calpain inhibition preserves myocardial structure and function following myocardial infarction. Am J Physiol Heart Circ Physiol. 2009 Nov; 297(5):H1744-51.
    View in: PubMed
    Score: 0.017
  83. Chronic matrix metalloproteinase inhibition following myocardial infarction in mice: differential effects on short and long-term survival. J Pharmacol Exp Ther. 2006 Sep; 318(3):966-73.
    View in: PubMed
    Score: 0.013
  84. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006 May 02; 113(17):2089-96.
    View in: PubMed
    Score: 0.013
  85. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol. 2006 Feb 15; 97(4):532-7.
    View in: PubMed
    Score: 0.013
  86. Left ventricular form and function: scientific priorities and strategic planning for development of new views of disease. Circulation. 2004 Oct 05; 110(14):e333-6.
    View in: PubMed
    Score: 0.012
  87. Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2003 Aug 05; 108(5):598-604.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.